Latest news with #JosephSchwartz
Business Insider
5 days ago
- Business
- Business Insider
Leerink Partners Keeps Their Buy Rating on uniQure (QURE)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on uniQure (QURE – Research Report) on June 3 and set a price target of $48.00. The company's shares closed yesterday at $14.96. Confident Investing Starts Here: Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Schwartz has an average return of 10.5% and a 42.05% success rate on recommended stocks. Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $38.40, implying a 156.68% upside from current levels. In a report released on June 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target. Based on uniQure's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.57 million and a GAAP net loss of $43.64 million. In comparison, last year the company earned a revenue of $8.49 million and had a GAAP net loss of $65.62 million Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year. Most recently, in March 2025, Jeannette Potts, the CLO of QURE sold 7,076.00 shares for a total of $72,812.04.
Yahoo
17-05-2025
- Business
- Yahoo
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company's ERT portfolio; this is likely the first business development deal in 2025. Before market open on Friday, BioMarin disclosed a definitive agreement to acquire Inozyme Pharma (INZY) for $4.00/share in an all-cash transaction for a total consideration of $270M. Leerink says it had been waiting for BioMarin to do some business development as it knew it was going to be part of their strategy moving forward, especially with James Sabry as Chief Business Officer. Overall, the firm thinks this first deal complements BioMarin's existing infrastructure and expertise in ERTs very nicely and looks forward to additional potential BD transactions to further supplement the company's pipeline. Leerink reiterates an Outperform rating on the shares. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on BMRN: Disclaimer & DisclosureReport an Issue BioMarin Pharmaceutical's Strategic Growth and Market Potential: A Buy Rating by Yun Zhong BioMarin says Inozyme deal to strengthen enzyme therapies portfolio BioMarin Acquires Inozyme Pharma for $270 Million BioMarin's acquisition of Inozyme to strengthen enzyme therapies portfolio BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M Sign in to access your portfolio
Yahoo
05-05-2025
- Business
- Yahoo
PTC stock slides on new data for Huntington's drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Shares in PTC Therapeutics fell by double-digits Monday morning as investors parsed new clinical trial results for an important Huntington's disease drug the biotechnology company has been developing. Results from the study showed PTC's drug lowered levels of a target protein associated with Huntington's, confirming an earlier readout. According to the company, the data also suggested 'trends' in benefit on scales designed to assess clinical outcomes. PTC said it would discuss with regulators whether it could seek an accelerated approval. However, analysts expect the company will need to conduct a Phase 3 study to better establish whether the treatment is actually slowing disease. The results PTC released Monday give a fuller look at a Phase 2 study dubbed PIVOT-HD, which randomized Huntington's patients to receive either placebo or one of two doses of the company's drug, PTC518. Treatment with PTC518 hit the study's main goal, which measure blood levels of a protein called huntingtin at 12 weeks. That lowering was then maintained through one year, the updated data show. Normally, huntingtin protein plays a variety of helpful functions in the brain. But when mutated in Huntington's disease, the protein can clump together in a manner that's toxic to nerve cells. Treatments like PTC518 are designed to degrade the nucleic acid blueprints that encode for the protein, thereby lowering levels. However, linking PTC518's effect on huntingtin protein to clinical benefit is harder to assess. For patients who were in an earlier, 'Stage 2' of disease, the data showed 'dose-dependent trends of benefit' versus placebo on a key scale measuring disease progression, PTC said. Among later, 'Stage 3' patients, there were similar trends in the low dose group, but not among patients given the higher dose. PTC said this might suggest a different treatment effect in Stage 3 patients versus Stage 2 individuals. The company also presented interim, 24-month results that compared study participants to a natural history control group. There, too, PTC said the data hinted at a clinical benefit. Favorable trends may not be enough to prove PTC518 is worthy of regulatory approval, though. 'There are no mentions of any associations between mHTT lowering and clinical outcomes, which we think is the most important aspect of this data readout,' wrote Leerink Partners analyst Joseph Schwartz in a client note Monday. 'As a reminder, the [Food and Drug Administration] told [PTC] that while they were aligned with [huntingtin] lowering in principle to support an accelerated approval pathway, they wanted to see associations with [huntingtin] lowering and clinical outcomes.' Kristen Kluska, an analyst at Cantor Fitzgerald, added in a separate note that she thought 'the market reaction today seems more focused on the potential for [accelerated approval] vs. focusing on whether or not these data are de-risking.' Shares in PTC were trading down by about 18% near mid-day Monday. Recommended Reading Novartis wagers billions of dollars on PTC Huntington's drug Sign in to access your portfolio
